BCL2 vs MCL1: Two Anti-Apoptotic Proteins Compared
BCL2 and MCL1 are anti-apoptotic BCL-2-family proteins that can bind pro-death partners. Their abundance, interactions and functional dependency are related but not identical measurements.
Quick Answer
BCL2 and MCL1 are anti-apoptotic BCL-2-family proteins that can bind pro-death partners. Their abundance, interactions and functional dependency are related but not identical measurements.
Shared Family, Different Dependencies
Both proteins can restrain apoptosis by binding pro-apoptotic partners. A cancer cell may depend more on one, both or neither under a particular condition.
Expression Is Not Dependency
Protein expression is not a direct measure of functional reliance. Experimental approaches such as BH3 profiling were developed to examine apoptotic priming and dependencies.
Key Takeaways
- ·BCL2 and MCL1 are related anti-apoptotic proteins.
- ·Expression and dependency are not interchangeable.
- ·Clinical implications require disease- and evidence-specific review.
Put these genes in pathway context
Frequently asked questions
What is the key idea in BCL2 vs MCL1: Two Anti-Apoptotic Proteins Compared?
BCL2 and MCL1 are anti-apoptotic BCL-2-family proteins that can bind pro-death partners. Their abundance, interactions and functional dependency are related but not identical measurements.
What should be kept with the result or mechanism?
BCL2 and MCL1 are related anti-apoptotic proteins. Expression and dependency are not interchangeable. Clinical implications require disease- and evidence-specific review.
References
Continue Reading
BCL2 Family Proteins and Cancer Cell Survival
5 min read
How MYC Drives Oncogenic Transcriptional Amplification in Cancer
5 min read
TP53 Mutations in Cancer: Function, Hotspots and Interpretation
6 min read
Top Tumor Suppressor Genes Explained
6 min read
BAX and BAK: Mitochondrial Gatekeepers of Apoptosis
3 min read
BH3 Mimetics Explained: Drugging the BCL-2 Family
3 min read
Choose your next research step
Move from this explanation into a gene profile, a pathway map, or the next evidence update.
BCL2 has 125+ trials currently recruiting on ClinicalTrials.gov. The GeneAnalyses digest summarises the new and changed ones each day.